Skip to content

Effect of Bed Bathing Methods on VRE Colonization in ICU Patients

The Effect of Two Different Bed Bathing Methods on Vancomycin-Resistant Enterococcus Colonization in Intensive Care Patients: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07364435
Enrollment
210
Registered
2026-01-23
Start date
2024-09-01
Completion date
2025-08-01
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vancomycin-Resistant Enterococcus

Brief summary

This randomized controlled trial aims to compare the effects of two different bed bathing methods on vancomycin-resistant Enterococcus (VRE) colonization in adult intensive care unit patients. A total of 210 patients were randomly assigned to receive either daily whole-body bathing with 4% chlorhexidine gluconate solution or daily bed bathing using disposable antibacterial body wipes. VRE colonization was monitored using skin swab cultures collected on days 7, 14, and 21. The results of this study may contribute to infection prevention strategies in intensive care units by identifying effective hygiene practices for reducing VRE colonization.

Detailed description

This study was designed as a randomized controlled trial conducted in the general intensive care units of a tertiary care hospital. Adult patients meeting the inclusion criteria were randomly assigned to one of two parallel groups. The experimental group received daily whole-body bed bathing with a 4% chlorhexidine gluconate solution, while the control group received daily bed bathing using disposable antibacterial body cleansing wipes. Randomization was performed to ensure comparable baseline characteristics between the groups. VRE colonization was assessed through skin swab cultures obtained at baseline and subsequently on days 7, 14, and 21. The primary outcome of the study was the rate of VRE colonization over time. Secondary analyses included the evaluation of patient-related factors such as age, length of stay, body mass index, and previous VRE history. All procedures were performed by trained nursing staff according to standardized protocols. The study was conducted following ethical approval obtained from the institutional ethics committee, and informed consent was obtained in accordance with ethical standards. The findings of this study aim to support evidence-based infection control practices in intensive care nursing.

Interventions

PROCEDUREBed Bath

Daily whole-body bed bathing performed as part of routine ICU care.

DEVICEDisposable antibacterial bed bath wipes

Daily whole-body bed bathing using disposable antibacterial body cleansing wipes as part of routine ICU care.

A 4% chlorhexidine gluconate solution used during the bed bathing procedure for whole-body skin antisepsis in ICU patients.

Sponsors

Özkan Kasap
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18 years and older * Patients admitted to the intensive care unit * Expected ICU stay of at least 48 hours * Patients requiring daily bed bathing

Exclusion criteria

* Known hypersensitivity to chlorhexidine * Extensive skin lesions or burns * Patients colonized or infected with VRE at ICU admission * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Vancomycin-Resistant Enterococcus (VRE) ColonizationBaseline, Day 7, Day 14, and Day 21The presence of vancomycin-resistant Enterococcus (VRE) colonization assessed by skin swab cultures obtained from intensive care unit patients. Cultures were collected at baseline and on days 7, 14, and 21 to compare the effect of two different bed bathing methods.

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORAyfer Ozbas, Prof.Dr.

T.C. DEMIROGLU SCIENCE UNIVERSITY

Baseline characteristics

Characteristic
Age, Continuous62.181 years
STANDARD_DEVIATION 18.168
Body Mass Index (BMI)21.780 kg/m²
STANDARD_DEVIATION 3.372
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
81 Participants
Sex: Female, Male
Male
62 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1050 / 105
other
Total, other adverse events
0 / 1050 / 105
serious
Total, serious adverse events
0 / 1050 / 105

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026